AOD-9604: Evidence, Safety, Dosing and Access Questions

AOD-9604, also called hGH fragment 176-191, is a peptide studied for fat metabolism and weight loss. Its evidence grade is C: human research exists, but no randomized trials are indexed in the retrieved PubMed set. It is not a GLP-1 medication, and available evidence is much thinner than for approved weight-loss drugs.

What it is

AOD-9604 is also known as hGH fragment 176-191 or human growth hormone fragment 176-191. It is a short peptide fragment related to the end portion of human growth hormone, and it has been discussed in obesity-drug development literature as a metabolic peptide 1, 2.

Names, class, and basic definition

The main names you may see are AOD-9604, AOD9604, hGH fragment 176-191, and human growth hormone fragment 176-191. The “hGH” part refers to human growth hormone, but AOD-9604 is not the full growth-hormone molecule 1.

AOD-9604 is usually discussed by patients as a “weight-loss peptide.” A more careful description is that it has been studied for fat metabolism and obesity-drug development, but the retrieved literature does not support treating it as a well-proven weight-loss medication 1, 2, 3.

How AOD-9604 differs from growth hormone and GLP-1 medications

AOD-9604 is not full growth hormone. Full growth hormone has broad endocrine effects, while AOD-9604 is a fragment that has been investigated separately in metabolic and drug-testing literature 1, 4.

AOD-9604 is also not a GLP-1 receptor agonist. Semaglutide, the active ingredient in Wegovy, Ozempic, and Rybelsus, works through the GLP-1 receptor; tirzepatide, the active ingredient in Zepbound and Mounjaro, works through GIP and GLP-1 receptors. AOD-9604 is discussed instead as a growth-hormone fragment 1, 2.

Mechanism of action

The proposed mechanism for AOD-9604 is related to fat metabolism, including proposed effects on lipolysis, which means fat breakdown. In humans, the retrieved evidence does not establish a clear clinical mechanism that proves weight loss 1, 2.

Proposed lipolysis and fat-metabolism mechanism

Reviews describe AOD-9604 as a metabolic peptide connected to the growth-hormone fragment 176-191 concept 1. That supports why researchers looked at fat metabolism, but it does not prove that a person using AOD-9604 will lose a predictable amount of weight.

This difference matters. A proposed pathway is a reason to study a compound; it is not the same as a proven clinical outcome. The retrieved PubMed set includes reviews, drug-testing papers, an animal osteoarthritis model, and cell-based work, but not randomized human weight-loss trials 3, 5, 6, 7.

What the current evidence can and cannot prove

The evidence can support a limited statement: AOD-9604 has been discussed and studied in human-related literature, drug-development literature, and analytical testing literature 1, 2, 4, 6. It cannot support a strong claim that AOD-9604 produces reliable weight loss in patients.

The retrieved evidence also cannot define a safety profile the way large human trials can. That is why any discussion of possible benefits has to be paired with uncertainty about side effects, interactions, product quality, and patient selection 3, 8.

Evidence

AOD-9604 has an evidence grade of C. That means human research exists, but the retrieved PubMed set found no randomized human trials.

Why a grade C rating is a caution signal, not a verdict

A grade C rating does not prove AOD-9604 fails. It means the evidence base is not strong enough to make confident patient-level claims about weight loss, dosing, or safety.

The retrieved records include reviews on AOD-9604 and obesity-drug development, but they do not provide randomized human efficacy results for weight loss 1, 2. A later review of approved and unapproved peptide therapies also supports a cautious approach to unapproved peptide claims in health and performance settings 3.

What the published records focus on

Some papers focus on laboratory detection and sports-drug testing rather than patient outcomes. For example, one study evaluated detection and in vitro metabolism of AOD9604, which helps identify the compound in a lab but does not show weight-loss effectiveness or patient safety 6.

Another drug-testing paper reported that AOD-9604 did not influence the WADA hGH isoform immunoassay. That is an assay interpretation finding, not evidence that AOD-9604 is effective or safe for weight loss 9.

There is also animal and cell evidence in the retrieved set. A rabbit osteoarthritis model studied intra-articular AOD9604 with or without hyaluronic acid, but animal joint findings cannot be converted into human weight-loss claims 7. A cell-based cancer-drug nanoparticle paper studied human growth hormone fragment 176-191 in MCF-7 breast cancer cells, but in vitro cancer-cell work cannot prove human benefit or safety 10.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-09.

Reported dosing ranges

No human dosing range for AOD-9604 can be responsibly extracted from the retrieved PubMed records. This section is a research-dose summary, not patient dosing advice.

This is one of the clearest practical points on AOD-9604: if a source gives a simple injection schedule without a clinician evaluation and without published support, it is not a reliable medical plan. For more context, see our guide to AOD-9604 peptide research and our article on buying AOD-9604 peptide.

Legal status

Our regulatory log holds no confirmed federal action for AOD-9604. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-09. See the full legal-status tracker for every compound we follow.

Safety

The honest safety answer is that AOD-9604 does not have the kind of large randomized human trial record that would define common side effects, rare risks, contraindications, or long-term outcomes. The retrieved evidence base is too thin for reassurance 1, 2, 3.

What human evidence can support

The retrieved human-related records support that AOD-9604 has been discussed in clinical-development and analytical contexts 1, 2, 4, 6. They do not establish a complete adverse-effect profile for people using it for weight loss.

Because the safety record is incomplete, side effects cannot be dismissed just because a compound is a peptide. Peptides can still have biologic activity, interact with medical conditions, or pose risks if the product is contaminated, mislabeled, or used without medical oversight 3, 8.

Why unapproved or unknown peptide products add risk

One drug-analysis report described identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by Belgian authorities, including AOD9604 8. That supports a real quality concern: a vial or capsule bought outside medical care may not contain what the label says.

• Identity risk: the product may not be the stated peptide, or may contain additional substances 8.
• Purity risk: impurities or degradation products may be present in unknown preparations 8.
• Sterility risk: injectable products require sterile manufacturing standards; a research-use vial is not the same as patient medication.
• Clinical risk: without a medical review, there may be no screening for pregnancy, endocrine disorders, cancer history, medication interactions, or other risk factors.

AOD-9604 also appears in sports-drug-testing literature, including mass-spectrometry and doping-control discussions 4, 11. That does not prove harm, but it is another reason athletes should not assume online peptide products are low-risk.

Interactions

No dedicated interaction studies for AOD-9604 were available in the retrieved PubMed set. That is not proof of no interactions; it means the interaction evidence is not well mapped.

Medication and condition review with a clinician

A clinician would normally review prescription drugs, supplements, weight-loss medications, hormone therapies, endocrine history, cancer history, pregnancy status, breastfeeding status, and metabolic conditions before considering a peptide or weight-management plan. The need for this kind of review is stronger when the published safety and interaction data are limited 3.

This matters for people already using medications that affect appetite, glucose, blood pressure, or hormones. The retrieved AOD-9604 records do not define how those combinations behave in humans.

Special caution for cancer history, pregnancy, breastfeeding, and endocrine disorders

One retrieved in vitro study involved human growth hormone fragment 176-191 in MCF-7 breast cancer cells as part of a doxorubicin-loaded nanoparticle experiment 10. That cell study does not show human cancer benefit or safety, but it is a reason to be careful about extrapolating in people with a cancer history.

The retrieved evidence also does not establish safety during pregnancy or breastfeeding, or in people with endocrine disorders. For a compound with limited human outcome data, absence of evidence should not be read as reassurance.

How to obtain it legally

AOD-9604 is not offered by Chia. We include it in our education library because patients ask about it, and because comparing thin evidence with better-studied options can help people make safer, more informed decisions.

Clinician evaluation and prescription process, where clinically appropriate

A medical access process starts with a health history, medication review, goals, risk screening, and a licensed clinician deciding whether any treatment is appropriate. A prescription is never guaranteed.

If medication is prescribed through Chia for a treatment we offer, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Compounded medications are not FDA-approved.

What a research-only vendor is not

A research-only vendor is not medical care. It does not replace a clinician’s review, a prescription decision, sterile patient-grade dispensing, follow-up, or help if side effects occur.

The concern is not just paperwork. Drug-analysis literature has described unknown pharmaceutical preparations containing peptide drugs, including AOD9604, which supports caution about identity and quality from non-medical sources 8.

Better-studied weight-loss options to discuss with a licensed provider

For weight management, better-studied options include GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. At Chia, our providers evaluate patients online for compounded semaglutide injection and compounded tirzepatide tablets or injection, when clinically appropriate.

Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus and is a GLP-1 receptor agonist. Tirzepatide is the active ingredient in Zepbound and Mounjaro and is a dual GIP/GLP-1 receptor agonist. Compounded formulations are not FDA-approved and do not have FDA-evaluated outcomes data.

If you are comparing peptide claims, our guides to weight-loss peptides and peptide side effects for weight loss may help you separate stronger evidence from early or indirect research.

Keep reading

Peptides

Can You Buy AOD-9604 Online? Safety, Legality, and Better-Studied Options

Peptides

Where to Get Peptide Injections Safely: Prescriptions, Telehealth, and What to Avoid

Weight Loss Medication

Peptides for Weight Loss: Side Effects, Risks, and What to Watch For